Skip Navigation



The Neuro-Ophthalmology division of the Wilmer Eye Institute specializes in treating patients with blurred vision caused by optic disorders, double vision caused by strokes and brain tumors, defects in the visual fields, and involuntary spasms of the face and eyelids. 

We also participate in groundbreaking research, working to apply new findings on neuro-ophthalmological to patient care solutions. Learn more about our research.

Conditions We Treat

Most neuro-ophthalmologic disorders require the interaction of the neuro-ophthalmologist with other physicians, particularly general neurologists, neurosurgeons and radiologists. The experts of the neuro-ophthalmology division at the Johns Hopkins Wilmer Eye Institute treat a variety of conditions including:
  • Optic nerve disorders, such as optic neuritis, ischemic optic neuropathy, compressive optic neuropathies, Leber optic neuropathy
  • Visual field defects related to strokebrain tumors or multiple sclerosis
  • Double vision from ocular motor nerve palsies
  • Myasthenia gravis
  • Thyroid eye disease
  • Orbital tumors
  • Blepharospasm and other involuntary facial movements
  • Pupillary abnormalities (e.g., anisocoria).

Providers by Location

The Johns Hopkins Hospital

Johns Hopkins Bayview Medical Center


Wilmer - Bethesda

Wilmer - Columbia

Wilmer - Frederick


The Wilmer Eye Institute Neuro-Ophthalmology Division is currently working on the following research projects.:

  • Dr. Amanda Henderson and Dr. Neil Miller are involved in translational research investigating potential treatment options for non-arteritic anterior ischemic optic neuropathy in an animal model of this condition.

    Dr. Henderson is also involved in clinical research evaluating the role of altered retinal inhibition in traumatic brain injury, as well as research in the area of ophthalmology trainee education."
  • Dr. Andrew Carey is presently working to validate methods for measuring vision loss, as well as a new home monitoring method for observiing vision loss for patients with pituitary tumors.
back to top button